NCT02632812View on ClinicalTrials.gov

Gastrointestinal Integrity After Naproxen + Rebamipide Versus Naproxen + Placebo

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 31, 2014

Primary Completion Date

November 30, 2014

Study Completion Date

November 30, 2014

Conditions
Gastrointestinal Lesions
Interventions
DRUG

Rebamipide effervescent granules

Rebamipide effervescent granules 100mg (oral), twice daily for 7 days

DRUG

Placebo effervescent granules

Placebo effervescent granules (oral), twice daily for 7 days

DRUG

Naproxen tablet

Naproxen tablet 550mg (tablet), twice daily for 7 days

Sponsors
All Listed Sponsors
lead

Biolab Sanus Farmaceutica

INDUSTRY